Localization of striatal excitatory amino acid binding site subtypes to striatonigral projection neurons

Sara J. Tallaksen-Greene a, Ronald G. Wiley b and Roger L. Albin a

a Department of Neurology, University of Michigan, Ann Arbor, MI (USA) and b Departments of Neurology and Pharmacology, DVMAC and Vanderbilt University, Nashville, TN (USA)

(Accepted 21 July 1992)

Key words: Striatum; Excitatory amino acid; Striatonigral projection; N-methyl-d-aspartate (NMDA); Volkensin

Quantitative autoradiography was used to examine the cellular localization of excitatory amino acid binding sites in the striatum following selective lesion of striatonigral projection neurons. Degeneration of striatonigral neurons was induced unilaterally by injection of the suicide transport toxin, volkensin, into the left substantia nigra. Twelve days following nigral volkensin injection there was a reduction of all excitatory amino acid binding site subtypes in the striatum ipsilateral to the injected nigra. The reduction in N-methyl-d-aspartate (NMDA) binding sites was significantly greater than the loss of D,L-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), kainate and metabotropic binding. These results indicate that there are NMDA, AMPA, metabotropic and kainate binding sites on striatonigral projection neurons and suggest that the NMDA subtype may be selectively enriched on striatonigral neurons.

The main afferent component of the basal ganglia is the striatum, which receives a massive cortical projection thought to be excitatory amino acidergic (EAAergic)1. EAAs act on at least four subtypes of EAA receptors classified on the basis of their pharmacological properties into N-methyl-d-aspartate (NMDA), D,L-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), metabotropic (MET) and kainate (KA) receptors34. Autoradiographic studies have identified high levels of all of these EAA receptor subtypes within the striatum1. Although it has been suggested that there are presynaptic EAA receptors in the striatum811, the majority of striatal EAA binding sites appear to be localized post-synaptically on striatal neurons14. Anatomical studies have shown that the striatum is composed predominantly of output neurons25. Two major populations of striatal projection neurons have been characterized on the basis of target structure; globus pallidus (GP) and substantia nigra (SN)12,21,22,26. However, the localization of EAA receptor subtypes to specific populations of striatal neurons has not been determined. In the present study, we used a suicide transport toxin, volkensin, to destroy striatonigral projection neurons in a fashion similar to Harrison et al.18. Following volkensin injection into the SN, we used quantitative autoradiography to examine the localization of EAA binding site subtypes in the rat forebrain.

Volkensin was prepared from Adenia volkensii as previously described31. Unilateral injections of the toxin (0.5–0.8 ng in 0.025–0.04 μl 0.1 M PBS, pH 7.4, + 0.1% Fast green) were made into the left SN of 6 adult, male Sprague-Dawley rats (195–260 g; Spartan Labs, Hastings, MI). Stereotaxic coordinates, determined using the rat atlas of Paxinos and Watson27, were 5.4 mm posterior to bregma, 1.8 mm to the left of the superior saggital suture and 8.2 mm ventral to the surface of the skull. Following a survival period of 12 days, the animals were sacrificed by decapitation, their brains were rapidly removed, frozen in powdered dry ice and stored at −70°C until use. 20-μM sections were cut using a cryostat microtome, thaw-mounted onto gelatin-coated slides and stored at −20°C for 24–48 h. Serial sections of the striatum were processed for EAA autoradiogra-
Fig. 1. Effects of volkensin lesion on the substantia nigra. The asterisk indicates the side ipsilateral to the volkensin injection. A: autoradiogram demonstrating total binding of \([\text{3H}]\text{SCH 23390}\) to \(D_1\) receptors in the substantia nigra. B: photomicrograph of a section taken from the same animal and stained with Cresyl violet.

The autoradiographic assays for EAA and \(D_1\) receptor binding sites were performed using previously described methods (Table I). For EAA autoradiography, sections were prewashed in buffer for 30 min at 4°C and dried under a stream of warm air prior to a 45 min incubation in ice-cold buffer containing radioligand and the appropriate blocking agents. The binding reaction was terminated by rapidly rinsing each slide with 4 squirts of buffer (4°C) followed by 2 squirts of cold 2.5% gluteraldehyde in acetone, and drying the sections under a stream of hot air. \(D_1\) receptor binding sites were assayed using the method of Richfield et al. (Table I). Sections were incubated in ligand solution for 180 min at room temperature, rinsed in buffer (10 min, 4°C), dipped in ice-water and dried under a stream of hot air. The slides were apposed to tritium-sensitive film (Hyperfilm, Amersham) and exposed for 1–2 weeks with known radioactive standards. The autoradiograms were analyzed using a computer-assisted densitometry program (MCID system, Imaging Research, St. Catharine’s, Ont., Canada). For each animal, all regions were analyzed in triplicate and specific binding was determined by subtracting non-specific from specific binding. EAA receptor subtypes were measured in the striatum, cerebral cortex and nucleus accumbens. For purpose of analysis, the striatum was divided into quadrants; dorsolateral (STR dl), dorso-medial (STR dm), ventromedial (STR vm) and ventrolateral (STR vl), and the cerebral cortex was divided into superficial (I–III; Cx out) and deep (IV–VI; Cx in) layers. Analysis of EAA binding data was performed using the SAS computer program (SAS Institute, Cary, NC, USA). For each ligand (Fig. 2), repeated measures ANOVA on two factors (region and treatment) was used to compare binding densities ipsilateral and contralateral to the lesion. The Bonferroni method of multiple comparisons was used to control for the overall (family-wise) error rate at alpha = 0.05. For each region (Table III), the ratio of ipsilateral to contralateral binding densities of the different EAA binding sites were compared using a one-way ANOVA followed by a Scheffé post-hoc F-test. The substantia nigra was examined using Cresyl violet stain to evaluate lesion placement and \(D_1\) receptor autoradiography to assess striatonigral degeneration. \(D_1\) binding data was analyzed with a paired Student’s t-test (significance level = \(P < 0.05\)).

Histological examination of the volkensin injection site revealed an area of cell loss and gliosis within the SN (Fig. 1B). \(D_1\) binding in the SN was profoundly reduced (> 90%) following volkensin injection (Fig. 1A, Table II). The effects of nigral volkensin injection on EAA binding site subtypes are shown in Fig. 2 and Table III. Analysis of variance indicated that in most
TABLE I

**EA4 and D₁ binding site assays**

<table>
<thead>
<tr>
<th>Binding site</th>
<th>Ligand</th>
<th>Specific activity</th>
<th>Conc.</th>
<th>Buffer</th>
<th>Blockers</th>
<th>Blank</th>
</tr>
</thead>
<tbody>
<tr>
<td>NMDA</td>
<td>[³H]Glutamate</td>
<td>50 Ci/mmol</td>
<td>65 nM</td>
<td>50 mM Tris-acetate pH 7.4, 4°C</td>
<td>2.5 µM quisqualate + 1 µM kainate</td>
<td>1 mM NMDA</td>
</tr>
<tr>
<td>Kainate</td>
<td>[³H]Kainate</td>
<td>58 Ci/mmol</td>
<td>60 nM</td>
<td>50 mM Tris-acetate pH 7.4, 4°C</td>
<td>100 µM kainate</td>
<td></td>
</tr>
<tr>
<td>AMPA</td>
<td>[³H]AMPA</td>
<td>60 Ci/mmol</td>
<td>16 nM</td>
<td>50 mM Tris-HCl+ 2.5 mM CaCl₂ + 30 mM KSCN pH 7.2, 4°C</td>
<td>1 µM glutamate</td>
<td></td>
</tr>
<tr>
<td>Metabotropic</td>
<td>[³H]Glutamate</td>
<td>50 Ci/mmol</td>
<td>100 nM</td>
<td>50 mM Tris-HCl+ 2.5 mM CaCl₂ + 30 mM KSCN pH 7.2, 4°C</td>
<td>100 µM NMDA + 10 µM AMPA</td>
<td>5 µM quisqualate</td>
</tr>
<tr>
<td>D₁</td>
<td>[³H]SCH 23390</td>
<td>83 Ci/mmol</td>
<td>0.55 nM</td>
<td>25 mM Tris-HCl+ 100 mM NaCl 100 mM MgCl₂ + 1 µM pargyline + 0.001% ascorbate pH 7.5, R.T.</td>
<td>1 µM cis-flupentixol</td>
<td></td>
</tr>
</tbody>
</table>

**TABLE II**

*D₁ binding in the substantia nigra following volkensin injection*

Data is expressed as specific binding in fmol/mg tissue (mean ± S.E.M.), n = 6. Percentage, (ipsilateral/contralateral) x 100. * Statistically different from control side (paired t-test, P < 0.0001). No significant difference between medial SN and lateral SN (1-way ANOVA, Schéffe's F-test).

<table>
<thead>
<tr>
<th>Region</th>
<th>Control side</th>
<th>Lesion side</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medial SN</td>
<td>1.28 ± 0.43</td>
<td>55 ± 30</td>
<td>4.2%</td>
</tr>
<tr>
<td>Lateral SN</td>
<td>1.30 ± 0.35</td>
<td>99 ± 63</td>
<td>7.6%</td>
</tr>
</tbody>
</table>

regions examined, loss of NMDA binding sites was significantly greater than the loss of AMPA, metabotropic or kainate binding sites (Table III, P < 0.05). In striatum, volkensin injection into the nigra reduced NMDA binding by approximately 50%. The other EAA binding site subtypes exhibited more modest reductions; up to 18% for AMPA, 27% for MET and 15% KA. Nigral volkensin injection significantly reduced NMDA and KA binding in nucleus accumbens (35% and 7%, respectively). The reductions in AMPA and MET binding in nucleus accumbens were not significant. In cerebral cortex, nigral volkensin reduced binding to the NMDA site nearly 45% and binding to the AMPA site almost 15%; changes in MET and KA binding were not statistically significant.

Our results indicate that there are NMDA, KA, AMPA and MET EAA binding sites on striatonigral projection neurons. These findings are consistent with electrophysiological studies that suggest that striatal EAA binding sites are located predominantly on striatal neurons.

**TABLE III**

*Comparison of percent differences in specific binding following volkensin injection into the substantia nigra*

Data is expressed as specific binding (ipsilateral/contralateral) x 100. For each region, the ratio of ipsilateral to contralateral binding densities of the different EAA binding sites were compared using a one factor ANOVA followed by a Scheffé F-test. In most regions, loss of NMDA binding sites was greater than the loss of other EAA binding sites. * Significant difference in the decrease of AMPA, MET or KA binding compared to NMDA binding, P < 0.05. There were no significant differences between binding to the AMPA, MET and KA sites. Cx out, superficial (I-III) frontoparietal cortex; Cx in, deep (IV-VI) frontoparietal cortex; STR dl, dorsolateral striatum; STR dm, dorsomedial striatum; STR vm, ventromedial striatum; STR vl, ventrolateral striatum; Acc, nucleus accumbens.

<table>
<thead>
<tr>
<th>Binding site</th>
<th>Region</th>
<th>Cx out</th>
<th>Cx in</th>
<th>STR dl</th>
<th>STR dm</th>
<th>STR vm</th>
<th>STR vl</th>
<th>Acc</th>
</tr>
</thead>
<tbody>
<tr>
<td>NMDA</td>
<td></td>
<td>56.6</td>
<td>55.4</td>
<td>45.6</td>
<td>55.3</td>
<td>63.4</td>
<td>51.3</td>
<td>65.4</td>
</tr>
<tr>
<td>AMPA</td>
<td></td>
<td>86.8</td>
<td>86.0</td>
<td>82.4</td>
<td>63.0</td>
<td>88.1</td>
<td>86.9</td>
<td>96.1</td>
</tr>
<tr>
<td>MET</td>
<td></td>
<td>87.1</td>
<td>85.8</td>
<td>73.2</td>
<td>80.2</td>
<td>83.5</td>
<td>82.3</td>
<td>88.9</td>
</tr>
<tr>
<td>KA</td>
<td></td>
<td>93.5</td>
<td>93.5</td>
<td>85.8</td>
<td>84.9</td>
<td>86.6</td>
<td>87.9</td>
<td>93.4</td>
</tr>
</tbody>
</table>
The relative magnitude of changes in striatal EAA binding that we observed following volkensin injection into the SN suggests that NMDA binding sites are enriched on striatongrial neurons. In addition to NMDA binding sites, striatongrial neurons have been shown to selectively express D1 receptors on both cell bodies and nerve terminals. Interestingly, NMDA receptor activation and D1 receptor activation have been shown to have opposite effects on the phosphorylation of DARPP-32, a neuronal phosphoprotein highly enriched in striatongrial neurons. Dopamine appears to differentially regulate the production of neuropeptides and the activity of striatongrial and striatopallidal neurons. The basis of the differential regulation of striatal projection neurons may be, in part, the selective expression of D1 and D2 receptor subtypes. Our data is consistent with the hypothesis that differential distribution of EAA receptor subtypes may also be important in the regulation of projection neuron subpopulations.

Heterogeneous distribution of EAA binding sites within the rat striatal complex has been previously reported. In the present study, we observed a heterogeneous distribution of changes induced by nigral volkensin injection. For example, NMDA binding was reduced ipsilateral to the lesion in all regions examined, whereas binding to the metabotropic site was decreased only in the dorsal striatum. Similarly, changes in binding to the different EAA receptor subtypes were inhomogeneous among regions. For example, in nucleus accumbens, nigral volkensin injection reduced NMDA and KA binding while binding to the AMPA and MET receptor subtypes was not significantly changed. These results suggest differential distribution of EAA binding site subtypes among striatal and nucleus accumbens neurons projecting to the SN.

Our findings suggest that there may be EAA binding sites on corticonigral neurons. Since all neurons projecting to SN may be susceptible to the toxic effects of volkensin, direct projections from the cerebral cortex may account for asymmetries in EAA binding in cerebral striatum induced by nigral volkensin injection. Alternatively, EAA binding site changes may be due to trans-synaptic degeneration induced by loss of striatongrial neurons that are recipients of cortical afferents.

There are several points to consider regarding possible limitations of the experimental paradigm used in this study. Volkensin has local toxic effects and in the present study, we noted a restricted area of cell loss at the site of injection (Fig. 1B). It is unlikely, however, that the changes we observed in striatal EAA binding were due to anterograde degeneration of nigrostriatal neurons (which are largely dopaminergic), since previous studies have reported that 6-hydroxy-dopamine lesion of nigrostrial neurons have no affect on binding to striatal EAA receptors. Leakage of volkensin from target neurons has been shown to occur with excessive doses. The question of trans-synaptic transfer of volkensin has been raised, but not proven. In the present study, it is possible that the reduction we observed in cortical EAA receptors following nigral volkensin injection may be due, at least in part, to degeneration of corticonigral neurons induced by the release of volkensin from striatal neurons. However, it is unlikely that corticostriatal neuron degeneration, if it did occur, could account for the changes we observed in striatal EAA binding sites since decortication has generally been shown to have little affect on the density of striatal EAA receptors. One exception, which is contradicted by the results of Greenamyre and Young, is a report by Errami and Nieuollen describing a 30% decrease in [3H]AMPA binding following decortication. Finally, it has been reported that volkensin may spread from the site of injection. In our study, histological examination did not reveal any volkensin-induced changes outside the boundaries of the SN. However, it is possible that the decrease we observed in NMDA and KA receptor binding sites in nucleus accumbens may be due to degeneration of neurons in nucleus accumbens projecting to regions surrounding the SN, such as the ventral tegmental area. In the present study, we have used volkensin in combination with quantitative autoradiography to characterize EAA receptor subtypes in relation to striatongral neurons. Our results are the first to characterize EAA receptor subtypes in relation to a specific population of striatal projection neurons.

The work was supported by NS 01300, NS 19613 and the Hereditary Disease Foundation. The authors would like to thank Dr. Roy T. St. Laurent for help with the statistical analysis.